1. Pink Sheet
  2. >>R&D

The IRA And US FDA: How Will Agency View Any Drug Development Changes?

 
• By Michael McCaughan

US biopharma companies are warning of significant changes in drug development priorities as they prepare for the implementation of new Medicare pricing measures enacted in 2022. Those changes will have ripple effects on the FDA, which may spark some responses.

changing minds
How will the FDA deal with industry as it adapts to the IRA? • Source: Shutterstock

The drug pricing reforms enacted by the Inflation Reduction Act are casting a long shadow over the drug development sector as 2023 begins.

It isn’t that drug development will necessarily be crushed by the new law. Just that things are likely to change...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

EU Critical Medicines Act May Include Investigational Products & Mandatory Redistribution Measure

 
• By Neena Brizmohun

The inclusion of investigational drugs in the Critical Medicines Act and new provisions on stockpiling are among the raft of amendments the European Parliament has made to the draft legislation.

Brazil Looks To AI And Digital Technologies To Revitalize Clinical Research Environment

 
• By Francesca Bruce

Brazil is planning to update its National Clinical Research Action Plan to make the country a more competitive location to conduct R&D.

Survey Highlights Long Road Ahead For UK To Becoming Clinical Trials Hub

 
• By Eliza Slawther

Commercial clinical trial sponsors have reported several challenges with setting up trials in the UK, which led the Health Research Authority and its partners to make “significant improvements,” to the process, a senior figure at the organization has said.

How England’s Cancer Vaccine Launch Pad Helped Scancell Speed Up Trial Patient Recruitment

 
• By Anabel Costa-Ferreira

As the CVLP prepares to support its third cancer vaccine trial, the Pink Sheet examined Scancell’s experience with the initiative, which the drug company used to recruit patients for its advanced melanoma vaccine trial.

More from Pink Sheet

EU Critical Medicines Act May Include Investigational Products & Mandatory Redistribution Measure

 
• By Neena Brizmohun

The inclusion of investigational drugs in the Critical Medicines Act and new provisions on stockpiling are among the raft of amendments the European Parliament has made to the draft legislation.

EU HTA Regulation: Key Gaps Identified In Support For Small Companies And Experts

 
• By Eliza Slawther

A meeting between the European Commission and industry stakeholders has revealed several areas of importance and lessons learned in relation to the EU Health Technology Assessment Regulation, which began to apply to certain medicinal products this year.

89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency

 
• By Bridget Silverman

The US FDA’s unprecedented publication of 89 recent CRLs for unapproved products comes with a promise to release future letters more promptly.